Enoxaparin sodium

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Percutaneous Coronary Intervention

Conditions

Percutaneous Coronary Intervention

Trial Timeline

Jan 1, 2004 → Sep 1, 2005

NCT ID

NCT00077844

About Enoxaparin sodium

Enoxaparin sodium is a phase 2/3 stage product being developed by Sanofi for Percutaneous Coronary Intervention. The current trial status is completed. This product is registered under clinical trial identifier NCT00077844. Target conditions include Percutaneous Coronary Intervention.

What happened to similar drugs?

2 of 2 similar drugs in Percutaneous Coronary Intervention were approved

Approved (2) Terminated (0) Active (0)

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00349180	Phase 3	Completed	Jun 1, 2006	—	Arthroplasty, Replacement, Hip
NCT00077844	Phase 2/3	Completed	Jan 1, 2004	Sep 1, 2005	Percutaneous Coronary Intervention
NCT00077805	Approved	Completed	Aug 1, 2003	—	Acute Ischemic Stroke
NCT00077818	Approved	Completed	Jun 1, 2002	—	Acute Coronary Syndrome
NCT00077753	Approved	Completed	Feb 1, 2002	Feb 1, 2007	Venous Thromboembolism

Competing Products

3 competing products in Percutaneous Coronary Intervention

See all competitors

Product	Company	Stage	Hype Score
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)	Novartis	Approved	50
Otamixaban (XRP0673) + Unfractionated Heparin	Sanofi	Phase 2	35